SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema, PharmD, PhDView Slideset
MRMichelle RudekPharmD, PhDSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)View Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment (#07) | Apostolos PapachristosView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches (#05) | Stefanie KrensView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: Food intervention to make therapy with pazopanib more patient friendly and affordable (#06) | Floor LubbermanView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhDView Slideset
RMRon MathijssenMD, PhDSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen, MD, PhDView Slideset
HGHoward GurneyMBBS, FRACPSlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald Gerritsen, MD, PhDView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACPView Slideset
SlidesetOncologyInternational Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018Abstract: A pharmacometric framework for dose individualisation of sunitinib in GIST (#O2) | Maddalena CentanniView Slideset
